NFE2L2 and Parkinson disease: Most notably, the pharmacological activator of Nrf2, dimethyl fumarate (DMF) was recently approved as a therapeutic treatment for multiple sclerosis (MS), under the name of Tecfidera, and has been researched extensively, with the goal of potentially repurposing DMF for other inflammatory diseases, such as Parkinson’s disease [108].